Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunotope and Immunovaccine, two clinical stage biotechnology companies, have received an official Notice of Allowance from the US Patent and Trademark Office for a new US Patent specific to the DPX-0907 therapeutic cancer vaccine.
Subscribe to our email newsletter
The new patent application titled ‘Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer’ gives additional intellectual property protection to the seven antigens used in Immunovaccine’s DPX-0907 – a therapeutic cancer vaccine indicated for patients with breast, ovarian or prostate cancers – in the US.
Immunovaccine acquired exclusive worldwide rights to license the seven antigens, believed to be present on the surface of breast, ovarian and prostate cancers and part of critical cancer cell processes, from Immunotope in 2009.
Immunovaccine is in the process of completing a Phase I clinical trial for DPX-0907.
Preliminary results have demonstrated the vaccine to be well tolerated and safe.
Additional safety and immune response data will be made available in the second quarter of 2011.